Form 4: Orchestra BioMed Holdings Insider Sells Shares
Statement of Changes in Beneficial Ownership
Darren Sherman, Director and Officer of Orchestra BioMed Holdings, Inc., reported the sale of 15,000 shares of common stock on June 1, 2026, executed under a Rule 10b5-1 trading plan.
Summary
- Darren Sherman, who holds positions as Director and Officer at Orchestra BioMed Holdings, Inc. (OBIO), has reported a transaction involving company stock.
- On June 1, 2026, 15,000 shares of common stock were disposed of.
- These sales were conducted under a pre-arranged Rule 10b5-1 trading plan, adopted on December 18, 2025, which is designed to comply with affirmative defense conditions.
- The reported sale price was a weighted average of $3.87 per share, with individual transactions occurring between $3.81 and $4.01.
- Following these transactions, Mr. Sherman beneficially owns 1,184,327 shares of common stock.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as the reported stock sale was executed under a pre-established Rule 10b5-1 trading plan, which is a standard and regulated method for insiders to sell shares.
Negatives
- Insider selling of company stock can sometimes be perceived negatively by the market, although in this case, it was executed under a pre-established trading plan.
Future Outlook
The filing does not contain forward-looking statements or guidance regarding future company performance. It solely reports a past transaction.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan indicates a structured approach to stock sales, often employed by executives to diversify holdings or manage personal finances without appearing to trade on material non-public information.
Stakeholder Impact
- Shareholders: The sale of shares by a director and officer, even under a Rule 10b5-1 plan, may lead to questions about insider confidence, though the plan itself is designed to mitigate concerns about timing based on non-public information.
Key Dates
| Date | Description |
|---|---|
| 12/18/2025 | Date Rule 10b5-1 trading plan was adopted by Darren Sherman. |
| 06/01/2026 | Date of transaction (sale of common stock). |
| 06/02/2026 | Date of signature on the Form 4 filing. |
Keywords
Orchestra BioMed Holdings, OBIO, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Beneficial Ownership, Darren Sherman
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.